louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05496192: A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer
Official title: A Phase II Study of Adjuvant Nivolumab Switch From Intravenous (IV) to Subcutaneous (SC) Use in Participants With Resected Stage III or Stage IV Melanoma or High Risk Invasive Urothelial Carcinoma Originating in the Bladder
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Melanoma
Urothelial Carcinoma
Keywords: Resected Invasive Urothelial Carcinoma
Nivolumab
Bladder
Melanoma
Adjuvant
Subcutaneous
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2022-08-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the switch from Nivolumab Intravenous (IV) infusions to Nivolumab Subcutaneous (SC) administration in participants with resected Stage IIIA/B/C/D or Stage IV melanoma or resected invasive Urothelial Carcinoma (UC) originating in the bladder who have high risk of recurrence.


Eligibility criteria: Inclusion Criteria:

* Participant must have Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
* Participants must be eligible for adjuvant therapy for melanoma or muscle-invasive Urothelial Carcinoma (UC) originating from the bladder.
* All participants must have disease-free status (DFS) documented by a complete physical examination and imaging studies within 4 weeks prior to treatment assignment.

Exclusion Criteria:

* History of ocular or uveal or mucosal melanoma.
* Upper tract UC (ureter, renal pelvis), non-muscle-invasive UC.
* Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment assignment.
* Untreated/unresected Central Nervous System (CNS) or leptomeningeal metastases.

Other protocol-defined inclusion/exclusion criteria apply

Primary outcomes:
measure: Proportion of Participants That Prefer Nivolumab SC at the First Assessment of Patient Preference Using Patient Experience and Preference Questionnaire (PEPQ) (Question 1)
timeFrame: Up to 24 hours after first full dose at Cycle 4, Day 1 (98 Days)
Secondary outcomes:
measure: Number of Participants with Adverse Events (AEs)
timeFrame: Up to 100 days following last dose of nivolumab (Up to Day 465)
measure: Proportion of Participants That Prefer Nivolumab SC at the Second Assessment of Patient Preference Using PEPQ (Question 1)
timeFrame: Up to 24 hours after fourth full dose at Cycle 5, Day 15 (140 Days)
Other outcomes:
Locations:
city: Essen
country: Germany
facility: Local Institution - 0020
state: North Rhine-Westphalia
city: Berlin
country: Germany
facility: Local Institution - 0001
city: Sevilla
country: Spain
facility: Local Institution - 0002
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT00172692: Observation and Evaluation of Chewing Velocity Changes on Soft Food Chewing Efficiency
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Mastication
Keywords: Chewing efficiency,
Gum chewing
Chewing velocity
Occlusal surface area
EMG
Jaw movement
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2005-09-15
Sex: ALL
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: OTHER

Brief summary: Soft food chewing does not require strong bite force. The number of chewing strokes and occlusal surface area of the posterior teeth are more important. Clinically, reduction of occlusal surface to protect the abutments of a fixed or removable partial denture or the implant supported teeth is often necessary. If a certain chewing ability is maintained with reduced occlusal area, changing chewing velocity might help. For this hypothesis, the effect of chewing velocity on soft food chewing ability would be observed first. The purpose of this study is to evaluate the deliberately changed chewing gum chewing velocity on the chewing ability of healthy subjects whose dental occlusal surface area is known. Twenty dental students (10 men and 10 women with an age range of 20-30 years) with healthy masticatory systems and complete dentition will be asked to chew HA containing chewing gum with habitual side teeth at the cycle time of 0.5 sec, 1.0 sec and 1.5 sec for 30, 40, and 50 times. Jaw movement, tooth contact, and muscle activities will be observed during chewing gum chewing. The distribution of HA particles in the gum bolus after each chewing session will be measured and regarded as the chewing efficiency of that subject. Occlusal surface area of the maxillary posterior teeth, chewing rate, chewing time, muscle activity and jaw lateral displacement will be related to the chewing efficiency with multiple regression analysis. The effects of practice due to changing of chewing rate will also be evaluated.

Detailed description: 1. HA containing chewing gum with habitual side teeth at the cycle time
2. The distribution of HA particles in the gum bolus after each chewing session will be measured and regarded as the chewing efficiency of that subject.

National Taiwan University Hospital, National Science Council

Eligibility criteria: Inclusion Criteria:

* Dental students
* Healthy masticatory system

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Yuh-Yuan Shiau, Professor
role: STUDY_CHAIR
References:
Clinical trial NCT03563092: Closed Suction Drain vs no Drain on Symptomatic Seroma Formation After Laparoscopic Inguinal Hernia Repair
Official title: Closed Suction Drain vs no Drain on Symptomatic Seroma Formation After Laparoscopic Inguinal Hernia Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Inguinal Hernia Without Obstruction or Gangrene
Keywords: Complete Inguinal Hernia
Inguinoscrotal Hernia
Laparoscopic hernia repair
Lead sponsor: GEM Hospital & Research Center
Sponsor class: OTHER
First posted: 2018-06-20
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Open-label, randomized clinical trial
Primary purpose: TREATMENT

Brief summary: The current study aims to determine whether a use of closed suction drain following laparoscopic inguinal hernia surgery performed for an inguinoscrotal variety can decrease the incidence of symptomatic seroma formation requiring interventions and thus, prevent postoperative morbidity.

Detailed description: Patients with laparoscopic inguinal repair, TEP as well as TAPP approach, which matches the inclusion criteria will be randomized intraoperatively, based on a complete assessment of eligibility, just before the mesh placement.

Patients recruited in closed suction drain arm will receive suction drain(14 French sizes) in preperitoneal space via a separate incision. The patients without drain arm, the regular postoperative course will be followed.

The drain will be removed once the output falls below 50 ml per day. Both groups will be followed up until three months post-surgery.

Clinical suspicion of seroma in symptomatic patients will be confirmed by ultrasound. Seroma will be managed conservatively till three weeks in the post-op period.

Eligibility criteria: Inclusion Criteria:

All patients having an inguinoscrotal hernia (complete type)

Exclusion Criteria:

Obstructed, incarcerated or strangulated hernia Patients unwilling to participate

Primary outcomes:
measure: Number of patients developing symptomatic seroma requiring intervention after surgery
timeFrame: Month 3
Secondary outcomes:
measure: Surgical site infection
timeFrame: Month 3
measure: Postoperative Pain
timeFrame: Day 1
measure: Recurrence
timeFrame: Month 3
Other outcomes:
measure: Factors affecting seroma
timeFrame: Day 7
Locations:
city: Coimbatore
country: India
facility: Sandeep C. Sabnis
state: Tamil Nadu
Study officials:
affiliation: Gem Hospital and Research Center, Coimbatore, India
name: Chinnusamy Palanivelu, MS,MCh,FRCS,FACS
role: STUDY_CHAIR
affiliation: Gem Hospital and research center, Coimbatore, India
name: Sandeep C. Sabnis, MS,DNB
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00766792: Removal of Uremic Toxins With Nocturnal Dialysis Versus Standard Dialysis
Official title: Removal of Uremic Toxins With Nocturnal Dialysis Versus Standard Dialysis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Renal Failure
Lead sponsor: University Hospital, Ghent
Sponsor class: OTHER
First posted: 2008-10-06
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Dialysis patients, who decide to switch from standard dialysis (3 times 240-270 min/week) to nocturnal dialysis (3 times 480 min/week), will be followed. In parallel a control group with patients staying on standard dialysis will be followed. The study will last 30 weeks. During this period blood samples (pre- and post-dialysis: 10 times; inlet and outlet of dialyzer: 3 times) will be collected on predetermined time points. Concentration of several uremic retention solutes will be determined.


Eligibility criteria: Inclusion Criteria:

* age \> 18 years

Exclusion Criteria:

* pregnancy

Primary outcomes:
measure: To evaluate what is more effective for removal of uremic toxins - nocturnal versus standard dialysis?
timeFrame: 30 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Ghent
country: Belgium
facility: University Hospital Ghent
Study officials:
affiliation: University Hospital, Ghent
name: Raymond Vanholder, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02049892: A Comparison of Large Diameter Metal Heads vs. Small Diameter Metal Heads vs/ Dual Mobility Total Hip Replacements
Official title: A Comparison of Large Diameter Metal Heads vs. Small Diameter Metal Heads vs/ Dual Mobility Total Hip Replacements
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Total Hip Replacement
Keywords: Total Hip Replacement
Metal Ion
2-5 years after surgery
Asymptomatic
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2014-01-30
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Orthopedic patients with prior hip replacement.

Brief summary: Does having a large diameter metal on polyethylene total hip replacement increase metal ion release. Larger metal heads are thought to have increased torsional forces on the trunion which would like release more metal ions. Increased metal ion levels have been associated with adverse local tissue reactions. Are there any differences comparing these groups to a dual mobility type total hip replacement.


Eligibility criteria: Inclusion Criteria:

* One total hip replacement, either a large metal head (\>40) or a small metal head (\<30) on a polyethylene bearing surface.
* 2 to 5 years s/p surgery minimum. No symptoms

Exclusion Criteria:

* Any other bearing surface besides metal on poly, no other joint replacements, symptomatic

Primary outcomes:
measure: Metal Ion levels
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
References:
Clinical trial NCT02268292: Home Bicycle Exercise and Aerobic Capacity
Official title: The Effects of Home Bicycle Exercise Program on Hyperlipidemia, Hypertension, Blood Sugar Control, Muscle Strength and Aerobic Capacity
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Metabolic Cardiovascular Syndrome
Keywords: Metabolic syndrome
Diabetes
Muscle strength
Aerobic exercise
Bicycle
Brain-derived neurotrophic factor
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2014-10-20
Enrollment: 37
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The subjects with MetS or type 2 diabetes were enrolled for this exercise-training program. All participators underwent an indoor bicycle exercise for twelve weeks. In addition to demographic data and biochemical tests were determined after an overnight fasting. Extension of muscle strength was detected in the dominant lower extremity.

Detailed description: This prospective open-labeled study was conducted in Taichung Veterans General Hospital. The adult participants with metabolic syndrome and/or type 2 diabetes were enrolled. MetS. The procedures were fully explained to all subjects before the cardiopulmonary exercise test. ll enrolled subjects received a scheduled twelve-week program for exercise-training program. A commercially available bicycle with an indoor bicycle trainer are used as the home exercise training modality. All medications were not allowed to be changed during the study.

Eligibility criteria: Inclusion Criteria:

* Adult with metabolic syndrome or type 2 diabetes

Exclusion Criteria:

* hyperglycemic crisis or HbA1c \> 12%;
* serum creatinine levels greater than 200 mmol/L;
* acute or chronic infectious diseases;
* limitations in the ability to undertake regular exercise

Primary outcomes:
measure: Metabolic syndrome
timeFrame: 12 weeks
Secondary outcomes:
measure: Muscle strength
timeFrame: 12 weeks
measure: Brain-derived neurotrophic factor
timeFrame: 12 weeks
measure: Arterial stiffness
timeFrame: 12 weeks
Other outcomes:
Locations:
Study officials:
References:
citation: Tsai SW, Chan YC, Liang F, Hsu CY, Lee IT. Brain-derived neurotrophic factor correlated with muscle strength in subjects undergoing stationary bicycle exercise training. J Diabetes Complications. 2015 Apr;29(3):367-71. doi: 10.1016/j.jdiacomp.2015.01.014. Epub 2015 Feb 7.
Clinical trial NCT07000292: MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
Official title: A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics and Efficacy of Subcutaneous Injection of MSC303 for the Treatment of Immune Glomerular Diseases
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Lupus Nephritis (LN)
ANCA-Associated Glomerulonephritis
Keywords: MSC303
Immune glomerular diseases
Lead sponsor: Shanghai Changzheng Hospital
Sponsor class: OTHER
First posted: 2025-06-02
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.

Detailed description: The primary endpoint of Phase Ib：Evaluate the safety of MSC303 in patients with Lupus Nephritis (LN）and ANCA-associated glomerulonephritis (ANCA-GN).

The primary endpoint of Phase II：Evaluate the change of Urine Protein/Creatinine Ratio (UPCR) in Week 12 compared with the baseline of MSC303 in patients with Lupus Nephritis(LN） and ANCA-associated glomerulonephritis (ANCA-GN).

Eligibility criteria: Inclusion Criteria:

1. Aged 18 to 65 years (including boundary values), gender unspecified；
2. Willing to participate voluntarily in this clinical study and with good compliance；
3. Regarding the criteria for the study diseases, meet the diagnostic criteria for any of the following diseases:

   1. Diagnosed with lupus nephritis(LN);
   2. diagnosed with ANCA-associated glomerulonephritis (ANCA-GN);
4. Sufficient organ function;

Exclusion Criteria:

1. History of severe allergic reaction to humanized monoclonal antibodies, or known allergy to any component of MSC303；
2. Active infection requiring antibiotic treatment；
3. Concomitant with other serious diseases；
4. Patients with congenital immunoglobulin deficiency；
5. Infection with human immunodeficiency virus (Human immunodeficiency virus (HIV)), hepatitis B or hepatitis C (including HBsAg, HBcAb positive with abnormal Hepatitis B Virus DNA (HBV DNA) or Hepatitis C virus RNA (HCV RNA ));
6. Other exclusion criteria may apply.

Primary outcomes:
measure: Phase Ib: safety Phase II: Urine Protein/Creatinine Ratio (UPCR)
timeFrame: 12 week
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Changzheng Hospital
state: Shanghai
Study officials:
affiliation: Shanghai Changzheng Hospital
name: Huji Xu, Ph.D, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00775892: SeriACL™ Device (Gen IB) Trial for Anterior Cruciate Ligament (ACL) Repair
Official title: A Multi-Center Open Label Study to Evaluate the SeriACL™ Device (Gen IB) for Primary Anterior Cruciate Ligament Repair
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Anterior Cruciate Ligament Reconstruction
Keywords: ACL
Ligament
Lead sponsor: Serica Technologies, Inc.
Sponsor class: INDUSTRY
First posted: 2008-10-20
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: A multi-center single-arm clinical trial is being conducted to evaluate SeriACL device safety and performance during total anterior cruciate ligament (ACL) reconstruction.


Eligibility criteria: Major Inclusion Criteria:

* Complete rupture of the ACL
* Passive flexion \>= 120° and passive extension = contralateral knee
* MCL grade 2 or less
* Pre-injury Tegner score \>= 4
* Informed Consent

Major Exclusion Criteria:

* Prior ACL reconstruction.
* Severe pain, swelling, or redness
* Complete PCL tear
* Complex menisci tears
* Contralateral knee ligament injury
* OA \> Grade II

Primary outcomes:
measure: Safety - Adverse Events
timeFrame: 12 months
measure: KT-1000 Arthrometer Knee Laxity
timeFrame: 12 months
Secondary outcomes:
measure: Knee Surveys
timeFrame: 12 months
Other outcomes:
Locations:
city: Salzburg
country: Austria
facility: Dr. Pierer Sanatorium
city: Leuven
country: Belgium
facility: UZ Leuven
city: Altentreptow
country: Germany
facility: Dietrich-Bonhöffer-Klinik
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover
city: Heidelberg
country: Germany
facility: ATOS Clinic
city: Heidelberg
country: Germany
facility: University of Heidelberg
Study officials:
affiliation: ATOS Clinic, Heidelberg
name: Hans Paessler, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: UZ Leuven, Belgium
name: Johan Bellemans, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Heidelberg University
name: Holger Schmitt, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dr. Pierer Sanatorium, Salzburg, Austria
name: Gerhard Oberthaler, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Dietrich-Bonhöffer-Klinik, Altentreptow, Germany
name: Uwe Pietzner, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hannover Medical School
name: Michael Jagodzsinki, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06263192: Pregnancy Prediction Using Anti-Müllerian Hormone in Intrauterine Insemination Cycles
Official title: Pregnancy Prediction in Non-sterile Patients After 4 Intrauterine Inseminations With Donor Using Anti-Müllerian Hormone
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility, Female
Anti-Mullerian Hormone Deficiency
Keywords: anti-mullerian hormone
infertility
intrauterine insemination
sperm donation
cumulative pregnancy rates
Lead sponsor: Clinica de la Mujer Medicina Reproductiva, Chile
Sponsor class: OTHER
Collaborators: name: Universitat Autonoma de Barcelona
First posted: 2024-02-16
Enrollment: 342
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 39
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study includes all patients between 25 and 39 years of age who have undergone IUI cycles with sperm donors

Brief summary: The goal of this study is to compare the cumulative pregnancy rates after 4 artificial inseminations with donor (IAD) in non-sterile women with plasma AMH levels \> and \< 1.1 ng/mL.


Eligibility criteria: Inclusion Criteria:

* IUI cycles with sperm donors either due to severe oligoasthenoteratozoospermia in the partner (defined as a motile sperm count (MSC) \< 5 million in the ejaculate) or for social reasons, with up to 4 attempts accounted for.

Exclusion Criteria:

* BMI \>30
* Infertility due to bilateral tubal factor
* Endometriosis grade II-IV.

Primary outcomes:
measure: Cummulative pregnancy rate
timeFrame: 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Fertty International
Study officials:
affiliation: Fertty International
name: Miguel Angel Checa
role: STUDY_DIRECTOR
References:
Clinical trial NCT01233089: Fitting Children With Contact Lenses
Official title: Quality of Life and Ease of Fit, Fitting Children With Contact Lenses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Refractive Error
Keywords: Myopia
contact lenses
children
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
Collaborators: name: University of Waterloo
First posted: 2010-11-03
Enrollment: 194
Sex: ALL
Minimum age (years): 8
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this three-month study is to compare the quality of life and ease of fit among children wearing investigational single-vision contact lenses, commercially marketed single-vision contact lenses, and commercially marketed multifocal contact lenses.


Eligibility criteria: Inclusion Criteria:

* Is between 8 and 16 years of age.
* Has the permission of a parent/legal guardian.
* Is willing and able to, or has a parent/legal guardian who is willing and able to help them, follow instructions and maintain the appointment schedule.
* Has had an ocular examination in the last two years.
* Has never worn contact lenses before.
* Has clear corneas and no active ocular disease.
* Can be successfully fit with the lenses to be used in the study.
* Has 20/25 or better best corrected visual acuity in each eye.
* Other protocol-defined inclusion/exclusion criteria may apply.

Exclusion Criteria:

* Has any ocular disease.
* Has a systemic condition that may affect a study outcome variable.
* Is using any systemic or topical medications that may affect ocular health.
* Has ocular or systemic allergies that could interfere with contact lens wear.
* Has any ocular pathology or condition that would affect the wearing of contact lenses.
* Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Visual acuity
timeFrame: 3 months
measure: Ease of fit
timeFrame: 1 week
measure: PREP score
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Waterloo
country: Canada
facility: University of Waterloo
state: Ontario
Study officials:
References:
citation: Paquette L, Jones DA, Sears M, Nandakumar K, Woods CA. Contact lens fitting and training in a child and youth population. Cont Lens Anterior Eye. 2015 Dec;38(6):419-23. doi: 10.1016/j.clae.2015.05.002. Epub 2015 Jun 9.